

John T. Moore, PhD
Chapel Hill, NC (919-448-5693)

Employment History

Consultant

SPV Therapeutics 2020 -
Eva Garland Consulting 2018 - 2019

Co-Founder/Scientific Advisor (Biotech)

Speedwell Bio, LLC 2020-
Open4meds (S-Corporation) 2018 -

North Carolina Central University, Durham, NC

Research Scientist 2018-

Shaw University, Raleigh, NC

Associate Professor of Biology 2015 -2018
Department of Natural Sciences and Mathematics
Courses Taught: Biochemistry, Genetics, Introductory Biology for Majors and Non-Majors, Senior Capstone, Introduction to Research

GlaxoSmithKline, RTP NC

Director, Target and Pathway Validation Group 2008-2015
Exploratory Cell Biology
Director, Discovery Technology Group 2006-2008
July 2006 - Promotion
Senior Research Investigator 2002-2006
September 2004 - Promotion
Research Investigator II, Systems Research 1998-2002
February 2001 - Promotion
Research Investigator I, Department of Biochemistry 1994-1998
September 1994 - Innovation Award and Promotion
Research Scientist, Department of Biochemistry 1993-1994
Burroughs Wellcome

New York State Dept of Health, Albany NY

Research Scientist 1991-1993
Department of Biochemistry

Bard College, Annandale NY

Assistant Professor 1988-1991
Department of Biology
Courses Taught: Genetics, Immunology, Cell Biology, Molecular Biology, Introductory Biology for Majors and Non-Majors

Education

1977-1981 Undergraduate Studies

University of Virginia

Charlottesville, Virginia

Graduated May 1981 with Honors

B.A. Biology

1981-1985 Graduate Studies

University of Minnesota/

Mayo Clinic Graduate School of Biomedical Sciences

St. Paul, Minnesota

Graduated December 1985

Ph.D. Cell and Developmental Biology

1986-1988 Postdoctoral Studies

University of California, Berkeley

Berkeley, California

Department of Genetics

Awarded NIH Postdoctoral Fellowship, Oncology

Invited Lectures

Advances in Toxicology and Drug Metabolism, Paris, FR 1999

ISSX, Annual Meeting, Los Angeles, CA 1999

Gordon Conference, Gene Expression, Providence, NH 2000

AAPS Annual Meeting, Indianapolis, ID 2000

Institute for Scientific Exchange, Atlantic City, NJ 2001

New York Academy of Sciences, NY, NY 2001

Knowledge Foundation, Orphan Nuclear Receptors, Sunnyvale, CA 2001

International Cytochrome P450 Meeting, La Grande Motte, FR 2001

Receptor-Ligand Interactions, IUBMB, Bergen, Norway 2002

North Carolina Central University, Graduate Seminar Series, Durham, NC 2002

National Institutes of Environmental Health and Science, RTP, NC 2002

Grand Rounds, Mount Sinai Hospital, New York City 2002

University of Delaware Graduate Seminar Series 2002

FASEB Summer Research Conference, Snowmass, CO 2003

Experimental Biology Meeting, San Diego, CA 2005

Workshop on Nuclear Receptors and NPC Disease, Dallas, TX, 2005

Duke Oncology Retreat, Durham, NC 2013

Stem Cells as Research Tools Conf., Speaker and Session Chair, Wash D.C. 2015

Fred Joyner Research Colloquium, Raleigh NC 2016

Postdoctoral Supervision

1. Dr. Kimberly Slentz-Kesler 1998-2000 Investigation of Estrogen-Receptor beta Function in Breast Cancer.

2. Dr. Kate Barrientos 2008-2012 Identification of eNOS Selective Ligands and Demonstration of their Utility in Pancreatic Cancer Therapy (collaboration with Dr. Chris Counter, Duke University).
3. Dr. Claire Jeong 2012-2015 Bioprinting Human Skin *in vitro* Using Five Dermal Cell Types (collaboration with Dr. Anthony Atala, Wake Forest Institute for Regenerative Medicine). Poster presented at 2015 Advances in Regenerative Medicine Conference.

Publications

64. Niture S., Lin M., Odera J.O., **John T. Moore**, Zhe H., Chen X, Suy S., Collins S.P., Kumar D. (2020) TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation. *Int J Biochem Cell Biol.* Nov 20:105885. doi: 10.1016/j.biocel.2020.105885. Epub ahead of print. PMID: 33227392.
63. Rios-Colon, L., Arthur E., Niture, S., Qi, Q, **John T. Moore** and Kumar, D. (2020) The Role of Exosomes in the Crosstalk between Adipocytes and Liver Cancer Cells. *Cells.* 9(9):1988. doi: 10.3390/cells9091988. PMID: 32872417; PMCID: PMC7563540.
62. **John T. Moore**, Pilkington W, Kumar D. (2020) Diseases with health disparities as drivers of COVID-19 outcome. *J Cell Mol Med.* 24(19):11038-11045. doi: 10.1111/jcmm.15599. Epub 2020 Aug 20. PMID: 32816409; PMCID: PMC7461081.
61. Niture, S., Gyamfi, M.A., Lin, M., Chimeh U., Dong, X., Zheng, W., **John T. Moore**, and Kumar, D. (2020) TNFAIP8 Regulates Autophagy, Cell Steatosis, and Promotes Hepatocellular Carcinoma Cell Proliferation. *Cell Death Dis.* 11(3):178. doi: 10.1038/s41419-020-2369-4. PMID: 32152268; PMCID: PMC7062894.
60. Niture S, **John T. Moore**, Kumar D. (2019) TNFAIP8: Inflammation, Immunity and Human Diseases. *J Cell Immunol.* 2019;1(2):29-34.
59. Smith, S., Channa J., Rickard, D., Nicodeme, E., Bui, T., Simmons, C. Coquery, C.M., Neil, J., Mayhew, D., Rajpal, D., Furst, S., Lee, J., Wu, D., Fraydoon Rastinejad, F., Willson, T., Viviani, F., Morris, D. **John T. Moore**, and Cote-Sierra, J. (2017) Tapinarof is a Natural AhR Agonist Resolves Skin Inflammation in Mice and Humans, *J. Invest. Dermatol.* doi: 10.1016/j.jid.2017.05.004, PMID: 28595996
58. Thomson, D., Wagner, A., Bantscheff, M., Benson, R., Dittus, L., Duempelfeld, B., Drewes, G., Krause, J., **John T. Moore**, Mueller, K., Poeckel, D., Rau, C., Salzer, E., Shewchuk, L., Hopf, C., Emery, J., and Muelbaier, M, (2017) Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines. *J. Med. Chem.* doi: 10.1021/acs.jmedchem.7b00137.

57. Lobera, M., Madauss, K., Pohlhaus, D. *et al.*, includes **John T. Moore** (2013) Selective Class IIa Histone Deacetylase Inhibition via a Nonchelating Zinc-Binding Group. *Nat Chem Biol* **9**, 319–325.
56. Rong, J., Klein, J.-L., Qiu, Y., Xie, M., Johnson, J., Waters, M., Zhang, V., Kashatus, J., Remlinger, K., Bing, N., Crosby, R., Jackson, T., Witherspoon, S., **John T. Moore**, Ryan, T., Neill, S., and Strum, J. (2012) Rosiglitazone Induces Mitochondrial Biogenesis in Differentiated Murine 3T3-L1 and C3H/10T1/2 Adipocytes, *PPAR Res.* 179454. doi: 10.1155/2011/179454.
55. Zuercher, W.J., Buckholz, R.G., Campobasso, N., Collins, J.L., Galardi, C.M., Gampe, R.T., Hyatt, S.M., Merrihew, S.L., **John T. Moore**, Oplinger, J.A., Reid, P.R., Spearing, P.K., Stanley, T.B., Stewart, E.L. Willson, T.M. (2010) Discovery of Tertiary Sulfonamides as Potent Liver X Receptor Antagonists, *J. Med. Chem.* **22**, 3412-3416.
54. Maglich, J.M., Lobe, D.C., **John T. Moore** (2009) The Nuclear Receptor CAR (NR1I3) Regulates Serum Triglyceride Levels under Conditions of Metabolic Stress, *J. Lipid Res.* **50**:439-445.
53. Wang, H., Li, H., Moore, L.B., Johnson, M.D., Maglich, J.M., Goodwin, B., Ittoop, O.R., Wisely, B., Creech, K., Parks, D.J., Collins, J.L., Willson, T.M., Kalpana, G.V., Venkatesh, M., Xie, W., Cho, S.Y., Roboz, J., Redinbo, M., **John T. Moore**, Mani, S. (2008) The Phytoestrogen Coumestrol is a Naturally-Occurring Antagonist of the Human Pregnane X Receptor (PXR). *Mol. Endocrinol.* **22**, 838-857.
52. Howarth, D.L., Law, S.H., Barnes, B., Hall, J.M., Hinton, D.E., Moore, L., Maglich, J.M., **John T. Moore**, Kullman, S.W. (2008) Paralogous VDRs in Teleosts: Transition of Nuclear Receptor Function. *Endocrinology*, **149**, 2411-2422.
51. **John T. Moore**, Collins, J. L., Pearce, K. H. (2006) The Nuclear Receptor Superfamily and Drug Discovery. *Chem. Med. Chem.* **1**, 504-523.
50. Mitchell, B.F., Mitchell, J.M., Chowdhury, J., Tougas, M., Engelen, S.M., Senff, N., Heijnen, I., **John T. Moore**, Goodwin, B., Wong, S., Davidge, S.T. (2005) Metabolites of Progesterone and the Pregnane X receptor: A Novel Pathway Regulating Uterine Contractility in Pregnancy. *Am. J. Obstet. Gynecol.* **192**, 1304-1313.
49. Xu, R., Lambert, M.H., Wisely, B.B., Warren, E.N., Weiner, E.E., Collins, J.L., Moore, L.B., Willson, T.M., and **John T. Moore** (2004) A Structural Basis for Constitutive Activity in the Human CAR/RXR α Heterodimer. *Molecular Cell*, **16**, 919-928.

48. Goodwin, B. and **John T. Moore** (2004) The Role of CAR: Detailing New Models. *Trends in Pharmacogenomics*, 25, 437-441.
47. Hummasti S, Laffitte BA, Watson MA, Galardi C, Chao LC, Ramamurthy L., **John T. Moore**, Tontonoz P. (2004) Liver X Receptors are Regulators of Adipocyte Gene Expression but not Differentiation. Identification of apoD as a Direct Target. *J. Lipid Res.*, 45, 616-625.
46. Maglich, J.M., Watson, J., McMillen, P.J., Goodwin, B., Willson, T.M., and **John T. Moore** (2004) The Nuclear Receptor CAR is a Regulator of Thyroid Hormone Metabolism During Caloric Restriction. *J. Biol. Chem.* 279, 19832-19838.
45. Maglich, J.M., Caravella, J.A., Lambert, M.H., Willson, T.M., **John T. Moore**, and Ramamurthy, L. (2003) The First Completed Genome Sequence from a Teleost Fish (*Fugu rubripes*) Adds Significant Diversity to the Nuclear Receptor Superfamily, *Nucl. Acids Res.*, 31, 4051-4058.
44. Maglich, J.M., Sluder, A.E., Willson, T.M., and **John T. Moore** (2003) Beyond the Human Genome: Analysis of Nuclear Receptor Function in Model Organisms and Application to Drug Discovery, *Am. J. of Pharmacogenomics*, 3, 345-353.
43. Williams, S.P., Bledsoe, R.K., Collins, J.L., Boggs, S., Lambert, M.H., Miller, A.B., **John T. Moore**, McKee, D.D., Moore, L., Nichols, J., Parks, D., Watson, M., Wisely, B., and Willson, T.M. (2003) X-ray Crystal Structure of the Liver X Receptor Ligand Binding Domain: Regulation by a Histidine-Tryptophan Switch. *J. Biol Chem.*, 278, 27138-27143.
42. Fuqua, S.A.W, Schiff, R., I. Parra, **John T. Moore**, Mohsin, S.K., Osborne, C.K., G.M. Clark, and Allred, D.C. (2003) Estrogen Receptor β protein in Human Breast Cancer: Correlation with Clinical Tumor Parameters. *Cancer Res.* 63, 2434-2439.
41. Maglich, J.M., Parks, D.J., Moore, L.B., Collins, J.L., Goodwin, B., Billin, A.N., Stoltz, C.A., Kliewer, S.A., Lambert, M.H., Willson, T.M., and **John T. Moore** (2003) Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes. *J. Biol Chem.*, 278, 17277-17283.
40. Henke, B.R., Consler, T.G., Go, N., Hale, R.L., Hohman, D.R., Jones, S.A., Lu, A.T., Moore, L.B., **John T. Moore**, Orband-Miller, L.A., Robinett, R.G., Shearin, J., Spearing, P. K., Stewart, E. L., Turnbull, P. S., Weaver, S.L., Williams, S.P., Wisely, G.B., and Lambert, M.H. (2002) A New Series of Estrogen Receptor Modulators That Display Selectivity for Estrogen Receptor. *J. Med. Chem.* 45, 5492-5505.
39. Maglich, J.M., Stoltz, C.M. Goodwin, B., Hawkins-Brown, D., **John T. Moore**, and Kliewer, S.A. (2002) Nuclear Pregnane X Receptor and Constitutive

- Androstane Receptor Regulate Overlapping but Distinct Sets of Genes Involved in Xenobiotic Detoxification. *Mol. Pharmacol.* 62, 638-646.
38. Bledsoe, R.K., Montana, V.G., Stanley, T.B., Delves, C.J., Apolito, C.J., McKee, D.D., Consler, T.G., Parks, D.J., Stewart, E.L., Willson, T.M., Lambert, M.H., **John T. Moore**, Pearce, K.H., and Xu, H.E. (2002) The Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mechanism of Receptor Dimerization and Coactivator Recognition. *Cell* 110, 93-105.
 37. **John T. Moore**, Maglich, J.M., Moore, L.B., and Kliewer, S.A. (2002) Functional and Structural Comparison of PXR and CAR, *Biochim. Biophys. Acta* (special issue on Cellular Regulation of Cytochrome P450s), 1619, 235-238.
 36. Wisely, G.B., Miller, A.B., Davis, R.G., Thornquist, A.D., Johnson, R., Spitzer, T., Sefler, A., Shearer, B., **John T. Moore**, Miller, A.B., Willson, T.M., Williams, S. (2002) Hepatocyte Nuclear Factor 4 is a Transcription Factor that Constitutively Binds Fatty Acids. *Structure* 10, 1225-1239.
 35. Willson, T.M. and **John T. Moore** (2002) Genomics v Orphan Nuclear Receptors – A Half-Time Report. *Mol. Endo.* 16, 1135-1144.
 34. **John T. Moore**, Goodwin, B., Willson, T.M., and Kliewer, S.A. (2002) Nuclear Receptor Regulation of Genes Involved in Bile Acid Metabolism. *Critical Reviews in Eukaryotic Gene Expression*, 12, 119-135.
 33. Moore, L. B., Maglich, J.M., McKee, D.D., Wisely, B., Willson, T.M., Kliewer, S.A., Lambert, M.H., and **John T. Moore**. (2002) PXR, CAR, and BXR Define Three Pharmacologically Distinct Classes of Nuclear Receptors. *Mol. Endo.* 16, 977-986.
 32. Xu, E., Stanley, T., Montana, V., Lambert, M.H., Shearer, B., Cobb, J.E., McKee, D.D., Galardi, C.M., Plunkett, K., Nolte, R., Parks, D.J., **John T. Moore**, Kliewer, S., Willson, T.M., and Stimmel, J.B. (2002) Crystal Structure of PPAR α Bound to a Corepressor Motif Reveals the Molecular Basis of Nuclear Receptor Antagonism. *Nature* 415, 813-817.
 31. Xu, H.E., Lambert, M.H., Montana, V.G., Moore, L.B., Collins, J., Oplinger, J. A., Kliewer, S.A., Gampe, R.T. Jr., McKee, D.D., **John T. Moore**, and Willson, T.M. (2001) Structural Determinants of Ligand Binding Selectivity Between the Peroxisome Proliferator-activated Receptors. *Proc. Natl. Acad. Sci. USA.* 98, 13919-13924.
 30. Deng, S.-J., Liu, W., Simmons, C.A., **John T. Moore**, and Tian, G. (2001) Identifying Substrates for Endothelium-Specific Tie-2 Receptor Tyrosine Kinase from Phage-Displayed Peptide Libraries for High Throughput Screening. *Comb. Chem. and High Thr. Scr.* 1, 525-533.

29. Maglich, J.M., Sluder, A., Guan, X., Shi, Y., McKee, D.D., Carrick, K., Kamdar, K., Willson, T.M., and **John T. Moore**. (2001) Comparison of Complete Nuclear Receptor Sets from the Human, *C. elegans*, and *Drosophila* Genomes. *Genome Biology* 2, 29.1-29.7.
28. Waters, K.M., Rickard, D.J., Riggs, B.L., Khosla, S., Katznellenbogen, J.A., Katznellenbogen, B.S., **John T. Moore**, and Spelsberg, T.C. (2001) Estrogen Regulation of Human Osteoblast Function is Determined by the Stage of Differentiation and Estrogen Receptor Isoform. *J. Cell. Biochem.* 83:448-462
27. Willson, T.M., Jones, S.A., **John T. Moore**, and Kliewer, S.A. (2001) Chemical Genomics: Functional Analysis of Orphan Nuclear Receptors in the Regulation of Bile Acid Metabolism. *Medicinal Research Reviews*, 21, 513-522.
26. **John T. Moore** and Kliewer, S.A. (2000) Use of the Nuclear Receptor PXR to Predict Drug Interactions. *Toxicology*, 153, 1-10
25. Slentz-Kesler, K., **John T. Moore**, Lombard, M., Zhang, J., Hollingsworth, R., and Weiner, M.P. (2000) Identification of the Human Mnk2 Gene (MKNK2) Through Protein Interaction with Estrogen Receptor β . *Genomics* 69, 63-71.
24. Su, J.-L., McKee, D.D., Ellis, B., Kadwell, S.H., Wisely, G.B., Moore, L.B., Triantafyllou, J.A., Kost, T.A., Fuqua, S., and **John T. Moore** (2000) Production and Characterization of an Estrogen Receptor β Subtype-Specific Mouse Monoclonal Antibody. *Hybridoma* 19 (6), 481-487.
23. Shewchuk, L.M., Hassell, A.M., Ellis, B., Holmes, W.D., Davis, R., Horne, E.L., Kadwell, S.H., McKee, D.D., and **John T. Moore** (2000) Structure of the Tie2 RTK Domain: Self-inhibition by the Nucleotide Binding Loop, Activation Loop, and C-Terminal Tail. *Structure* 8, 1105-1113.
22. Spencer, T.A., Li, D., Russel, J.S., Collins, J.L., Bledsoe, R.K., Consler, T.G., Moore, L.B., Galardi, C.M., McKee, D.D., **John T. Moore**, Watson, M.A., Parks, D.J. Lambert, M.H., and Willson, T.M. (2001) Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXR α . *J. Med. Chem.* 44, 886-897.
21. Parra, I., Schiff, R., Su, J.-L., **John T. Moore**, Moshin S., Allred, D., and Fuqua, S. (2000) Estrogen Receptor β Expression and Function in Breast Cancer. *Cancer Research*, 59, 5425-5428.
20. Jones, S.A., Moore, L.B., Shenk, J.L., Wisely, G.B., Hamilton, G.A., McKee, D.D., Tomkinson, N.C.O., LeCluyse, E.L., Lambert, M.H., Willson, T.M., Kliewer, S.A., and **John T. Moore**. (1999) The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor that has Diverged through Evolution. *Mol. Endo.*14, 27-39.

19. Fuqua, S.A.W., Schiff, R., Parra, I., Friedrichs, W.E., Su, J.-L., McKee, D.D., Slentz-Kesler, K., Moore, L.B., Willson, T.M., and **John T. Moore** (1999) Expression of Wild-type Estrogen Receptor β and Variant Isoforms in Human Breast Cancer. *Cancer Res.* 59, 5425-5428.
18. Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., **John T. Moore**, and Kliewer, S.A. (1998) The Human Orphan Nuclear Receptor PXR is Activated by Compounds that Regulate CYP3A4 Gene Expression and Cause Drug Interactions. *J. Clin. Invest.* 102, 1016-1023.
17. Kliewer, S.A., **John T. Moore**, Wade, L., Staudinger, J.L., Watson, M.A., Jones, S.A., McKee, D.D., Oliver, B.B., Willson, T.M., Zetterstrom, R.H., Perlmann, T., and Lehmann, J.M. (1998) An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway. *Cell* 92, 73-82.
16. **John T. Moore**, McKee D.D., Slentz-Kesler, K., Moore L., Jones S., Horne, E.L., Su, J.-L., Kliewer S., Lehmann J., Willson T. (1998) Cloning and Characterization of Human Estrogen Receptor β Isoforms. *Biochem. Biophys. Res. Comm.* 247, 75-78.
15. **John T. Moore**, Davis, S.T., and Dev, I. (1997) β -Lactamase is a Highly Versatile Genetic Reporter for Eukaryotic Cells. *Anal. Biochem.* 247, 203-209.
14. McGaughey, K.M., Wheeler, L. J., **John T. Moore**, Maley, G.F., Maley, F., and Mathews, C.K. (1996) Protein-Protein Interactions Involving T4 Phage-Coded Deoxycytidylate Deaminase and Thymidylate Synthase. *J. Biol. Chem.* 271, 23037-23042.
13. Sundseth, R. Joyner, S., **John T. Moore**, Dornsife, R., and Dev, I. (1996) Anti-HIV Agent 3'-Fluorothymidine Induces DNA Damage and Apoptosis in Human Lymphoblastoid Cells. *Antimicrob. Agents and Chemo.* 40, 331-335.
12. **John T. Moore**, Jaroslaw, J.M., Changchien, L., Maley, G.F., and Maley, F. (1994) Identification of a Site Necessary for Allosteric Regulation in T4-Phage Deoxycytidylate Deaminase. *Biochemistry* 33, 2104-2112.
11. **John T. Moore**, Maley, G., and Maley, F. (1993) Modified Unique Site Elimination Mutagenesis. *Anal. Biochem.* 208, 402-403.
10. **John T. Moore**, Uppal, A., Maley, G., and Maley, F. (1993) Avoidance of Inclusion Bodies in a High-Expression System. *Prot. Exp. Purif.* 4, 160-163.
9. **John T. Moore**, Silversmith, R.E., Maley, G., and Maley, F. (1992) T4-Phage Deoxycytidylate Deaminase Contains Two Zinc Atoms. *J. Biol. Chem.* 268, 2288-2291.

8. **John T. Moore**, Natzle, J., Fristrom, D., and Fristrom, J. (1990) Characterization of a Gene Involved in *Drosophila* Imaginal Disc Differentiation. *Dev. Genetics* 11, 299-309.
7. Natzle, J., Fristrom, J., Fristrom, D., **John T. Moore**, Osterbur, D., Paine-Saunders, S., and Withers, D. (1989) Properties of Genes Expressed During Ecdysone-Induced Imaginal Disc Morphogenesis in *Drosophila*. *Mol. Biol. Dev.* 66, 336-397.
6. Norvitch, M.E., Harvey, S., **John T. Moore**, and Wieben, E.D. (1988) Processing of Two Protein Precursors Yields Four Mature Guinea Pig Seminal Vesicle Secretory Proteins. *Biol. Reprod.* 38, 1155-1164.
5. **John T. Moore**, Hagstrom, J., McCormick, D.J., Harvey, S., Madden, B., Holicky, E., Stanford, D.R., and Wieben, E.D. (1987) The Major Clotting Protein from Guinea Pig Seminal Vesicle Contains Eight Repeats of a 24-Amino Acid Domain. *Proc. Natl. Acad. Sci. USA* 84, 6712-6714.
4. **John T. Moore**, Veneziale, C.M., and Wieben, E.D. (1986) The Effects of Androgen on the Transcription of Cell-Specific Genes of Guinea Pig Seminal Vesicle Epithelium. *Mol. and Cell. Endo.* 46, 205-214.
3. **John T. Moore**, Norvitch, M.E., and Veneziale, C.M. (1985) The cDNA Cloning of a 55kD Protein from Guinea Pig Seminal Vesicle: Evidence that the Protein is the Precursor of the 25kD Clotting Factor. *J. Biol. Chem.* 260, 3826-3832.
2. Epperly, M., Barham, S.S., **John T. Moore**, Holicky, E., Norvitch, M.E., and Veneziale, C.M. (1985) The Growth of Individual Seminal Vesicle Epithelial Cells and Their Proliferation. *Proc. Soc. Exp. Biol. Med.* 178,443-456.
1. **John T. Moore**, Norvitch, M.E., Wieben, E.W., and Veneziale, C.M. (1984) Expression of a Secretory Protein During Androgen-Induced Cell-Growth. *J. Biol. Chem.* 259, 14750-14756.

Pre-publications (Open Source journal)

Ward, A., Kamegne, M., (Shaw University undergraduate researchers), Dillard, P., **John T. Moore** (2019) Mutational Analysis of an Intrinsically Disordered Region in the *E. coli* Phosphatase CheZ, a Regulator of Chemotaxis (2019) doi:<https://doi.org/10.1101/607010>

Williams K.L. (Shaw University undergraduate researcher), Wells, C.I., and **John T. Moore** (2018) Identification of Kinase Inhibitors that Regulate Nuclear Receptor Nurr1 (NR4A2) Cellular Activity. Bioarchives bioRxiv doi:10.1101/420976

Book Chapters

1. **John T. Moore**, Collins, J.L., Pearce, K.H. (2005) The Nuclear Receptor Superfamily and Drug Discovery, First Reference in Chemical Biology, Kapoor and Weiss, eds.
2. **John T. Moore**, Willson, T.M., and Kliewer, S.A. (2002) The Physiological Role of PXR in Xenobiotic and Bile Acid Homeostasis. Elsevier Press.
3. **John T. Moore**, and Kliewer, S.A. (2000) Use of the Nuclear Receptor PXR to Predict Drug Interactions. In "Advances in Molecular Toxicology-2" Claude Reiss, ed. (VSP Int. Science Publishers).
4. Veneziale, C.M., Epperly, M., Barham, S.S., Norvitch, M.E., and **John T. Moore** (1984) Seminal Vesicle Epithelia: Individual Cell Growth and Replenishment. In "Control of Cell Growth and Proliferation", C.M. Veneziale, ed. (Van Norstrand Reinhold Press) pp. 1-10.

Patents and Applications

1. Inderjit Dev, **John T. Moore**, and Phiroze Sethna. Tissue-Specific Transcription of a DNA Sequence Encoding a Heterologous Enzyme for use in Prodrug Therapy to Lung Cancer, International Patent Application #WO 97/19183, Publication date, 1997.
2. Inderjit Dev, **John T. Moore**, and Carol-Ann Ohmstede. Vector Consisting of a Transcriptional Regulatory DNA Sequence Linked to a DNA Sequence Encoding β -Lactamase for Enzyme-Prodrug Therapy, International Patent Application #WO 97/19180, Publication date, 1997.
3. Inderjit Dev, **John T. Moore**, and Carol-Ann Ohmstede. Enzyme Gene Therapy Catalysing Prodrug Extracellular Conversion, International Patent Application #WO 97/191804, Publication date 1998.
4. Steven Kliewer, Jodi M. Maglich, **John T. Moore**, Linda B. Moore, Timothy M. Willson, and Michael Conger. Nonhuman Pregnane X Receptor Sequences for use in Comparative Pharmacology. Patent Case No. PU3855WO. Publication date 24 Nov. 2002.
5. Jason A. Holt, Jodi M. Maglich, Michael M. Conger, Guy Nash, and **John T. Moore** (2002) Mouse Farnesoid X Receptor Sequences for use in Comparative Pharmacology, Application No: PCT/US02/2262; Patent Case No. PU3856/WO, Publication date January 17, 2003.
6. Randy K. Bledsoe, Ann Miller, **John T. Moore**, Linda Moore, Shawn P. Williams, Bruce B. Wisely. Crystallized LXR Polypeptide in Complex with a Ligand and Screening Methods Employing Same. Publication number US 2004/0018560 A1, Publication date January 29, 2004.
7. Jodi M. Maglich and **John T. Moore**. Composition and Methods for Regulating Thyroid Hormone Metabolism and Cholesterol and Lipid Metabolism via the Nuclear Receptor CAR. Application No.: PCT/US03/06089 Patent Case No. PU4591/WO, Publication date May 19, 2005.

8. Jones, S.A., Liu, Y., and **John T. Moore**. Compositions and Methods for Treatment of Fibrosis. Publication number WO 2005/032549 A1, Publication number US2004/029748. Publication date, April 14, 2005.